HAYWARD, Calif., April 14 Metabolex, Inc., abiopharmaceutical company focused on the discovery and development ofproprietary new medicines for the treatment of metabolic diseases, announcedtoday that Donald M. Hill has joined the company as chief financial officer.Mr. Hill brings extensive financial and strategic planning experience toMetabolex, including expertise in business development, treasury managementand controllership of large operating divisions. Mr. Hill joins Metabolexfollowing more than 20 years in finance and corporate development managementroles at Merck & Co., Inc., most recently as Assistant Treasurer, GlobalCapital Markets.
"The appointment of Don expands the depth of our already strong managementteam," said President and Chief Executive Officer Harold Van Wart, Ph.D."Don's experience as a leader in a well respected, financially sophisticatedpharmaceutical company, his experience in business development, and his stronganalytical skills and strategic financial vision will be critical for us as weexpand our product pipeline and move our clinical product candidates towardscommercialization. With the company's four clinical product candidates andactive discovery and preclinical development programs, Don's skills infinancial planning and strategic product development will be invaluable."
Mr. Hill is a Chartered Financial Analyst (CFA), and holds a B.A. from theUniversity of California, Berkeley and a Masters degree from the Sloan Schoolof Management at the Massachusetts Institute of Technology.
Metabolex is a privately-held biopharmaceutical company focused on thediscovery and development of proprietary new medicines for the treatment ofmetabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawnon its deep understanding of diabetes to create a large database of genesinvolved in diabetes and to build a rich pipeline of product candidates anddrug discovery targets. The company has four clinical-stage compounds:MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial;MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently beingstudied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, whichhas just commenced a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive rightto develop and commercialize MBX-102/JNJ 39659100. For additional informationabout Metabolex and its development pipeline, visit http://www.metabolex.com.
SOURCE Metabolex, Inc.